3847-29-8

Basic information

• Product Name: ERYTHROMYCIN LACTOBIONATE (200 MG)
• Synonyms: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione (2R,;Erythromycin lactobionate;Lactose azithroMycin;ERYTHROMYCIN LACTOBIONATE (200 MG);4-o-beta-d-galactopyranosyl-d-gluconicacicompd.witherythromycin(1:1);4-o-beta-d-galactopyranosyl-d-gluconicacidcompd.witherythromycin;erythromycinmono(4-o-beta-d-galactopyranosyl-d-gluconate)(salt);lactobionicacid,compd.witherythromycin(1:1)
• CAS NO: 3847-29-8
• Molecular Formula: C₁₂H₂₂O₁₂*C₃₇H₆₇NO₁₃
• Molecular Weight: 1092.22
• EINECS: 223-348-7
• Product Categories: Peptide Synthesis/Antibiotics;API
• Mol File: 3847-29-8.mol
• Article Data: 1

Chemical Properties

• Melting Point: 145-150°
• Boiling Point: 818.4 °C at 760 mmHg
• Flash Point: 448.8 °C
• Appearance: /
• Density: 0.9083 (rough estimate)
• Vapor Pressure: 4.94E-31mmHg at 25°C
• Refractive Index: 1.5300 (estimate)
• Storage Temp.: Refrigerator
• Solubility: Soluble in water, freely soluble in anhydrous ethanol and in methanol, very slightly soluble in acetone and in methylene chloride.
• Water Solubility: >20g/L(21 oC)
• CAS DataBase Reference: ERYTHROMYCIN LACTOBIONATE (200 MG)(CAS DataBase Reference)
• NIST Chemistry Reference: ERYTHROMYCIN LACTOBIONATE (200 MG)(3847-29-8)
• EPA Substance Registry System: ERYTHROMYCIN LACTOBIONATE (200 MG)(3847-29-8)

Safety Data

• Hazardous Substances Data: 3847-29-8(Hazardous Substances Data)

Usage

Description

ERYTHROMYCIN LACTOBIONATE (200 MG) is a water-soluble salt derived from the erythromycin base, prepared by reacting with lactobiono-σ-lactone. It is an amorphous powder that is freely soluble in water and alcohol and slightly soluble in ether. This macrolide antibiotic inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, making it effective against various bacterial genera such as Streptococcus, Staphylococcus, and Haemophilus. It is known to potently inhibit the cytochrome P450 isoform CYP3A4, affecting the metabolism of numerous clinically relevant medications. Erythromycin lactobionate is typically used for intraperitoneal or intravenous injections and is available under the brand names Erythrocin (Abbott) and Erythrocin (Hospira).

Uses

Used in Pharmaceutical Industry:
ERYTHROMYCIN LACTOBIONATE (200 MG) is used as an antibiotic for the treatment of serious infections. It helps reduce the prevalence of drug-resistant bacteria and maintains the efficacy of other antibacterial drugs. The antibiotic is administered intravenously to achieve high plasma levels, making it effective against a wide range of bacterial infections.
Used in Medical Treatments:
ERYTHROMYCIN LACTOBIONATE (200 MG) is used as a macrolide antibacterial agent to inhibit bacterial protein synthesis by targeting the 50S ribosomal subunit. This action blocks the progression of nascent polypeptide chains, effectively treating various bacterial infections. It is particularly useful in cases where other antibiotics may not be as effective or when there is a need to target specific bacterial genera.

Originator

Erythrocin,Abbott,US,1954

Manufacturing Process

A solution of erythromycin free base is prepared by dissolving 8.0 grams of erythromycin in 25 cc of acetone. 4.0 grams of lactobiono-delta-lactone is dissolved in 25 cc of water. The free lactobionic acid is formed in this solution and it has the molecular formula C12H22O12. The two solutions are mixed and evaporated to a gummy residue. This residue is dissolved in 60 cc of water and the solution is frozen and dried in vacuum by lyophilization. The dried residue of erythromycin lactobionate is a white amorphous powder and weighs 11.7 grams. The reaction product has an activity against B. subtilis of 420units per milligram. Its solubility in water is about 200 mg/cc and the melting point of the white powdery reaction product is 145° to 150°C.

Therapeutic Function

Antibacterial

InChI:InChI=1/C37H67NO13.C12H22O12/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;3-10,12-20H,1-2H2,(H,21,22)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;3-,4-,5+,6+,7-,8-,9-,10-,12+/m11/s1

Upstream product

• 114-07-8 erythromycin 
• 96-82-2 lactobionic acid 

Relevant articles and documents

HYDRATES OF ERYTHROMYCIN SALTS, THE PREPARATION AND THE USE THEREOF

The present invention relates to a macrolide derivative as well as preparation and use thereof. The macrolide derivative of the present invention, i.e., a hydrate of erythromycin salts, has a molecular formula of C37H67NO13·A·nH2O, n=1.0-11.0, in which A is an organic acid or an organic acids, selected from lactobionic acid, thiocyanic acid, maleic acid, fumaric acid, thiocyanic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, nicotinic acid, lactic acid, citric acid, tartaric acid, aspartic acid, glutamic acid and phosphoric acid, the hydrate has good water solubility and better storage stability, which is suitable for the manufacture of a medicament for the treatment and prophylaxis of infectious diseases in human or animal caused by Gram-positive or negative bacteria.